Lucitanib

CAS: 1058137-23-7

Ref. 3D-ISB13723

Informação sobre produto

• Nome: Lucitanib
• Sinónimos: 1-Naphthalenecarboxamide, 6-[[7-[(1-aminocyclopropyl)methoxy]-6-methoxy-4-quinolinyl]oxy]-N-methyl-, 6-[[7-[(1-Aminocyclopropyl)methoxy]-6-methoxy-4-quinolinyl]oxy]-N-methyl-1-naphthalenecarboxamide, AL 3810, E 3810

Descrição

Lucitanib is a potent anti-tumor agent that inhibits the growth of cancer cells by inhibiting the production of vascular endothelial growth factor receptor 1 (VEGFR1). It also has antiangiogenic properties. Lucitanib has been shown to inhibit the proliferation of cancer cells in vitro and in vivo. A mouse tumor model was used to study the effects of lucitanib, which showed a significant inhibition of tumor size. In addition, lucitanib inhibited IL-2 receptor expression, leading to an increase in apoptosis of T lymphocytes and natural killer cells. The drug also showed potent antitumor activity against carcinoma cell lines in vitro. The LC-MS/MS method was used for identification and quantification of lucitanib in biological samples from breast cancer patients.

• Marca: Biosynth

Propriedades químicas

• Peso molecular: 443.49 g/mol
• Fórmula: C₂₆H₂₅N₃O₄
• Pureza: Min. 95%